APLM APOLLOMICS INC.

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.

H.C. Wainwright 26th Annual Global Investment Conference

Format: Company presentation

Presentation Date & Time: Available on demand as of September 9, 2024 at 7:00 am ET

Presenters: Guo-Liang Yu, PhD, Chairman and Chief Executive Officer and Matthew Plunkett, PhD, Chief Financial Officer

Webcast: Click

Management will be available for virtual one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to request meetings. The Company’s current presentation may be accessed on the Company website on the page under the Investors section.

About  

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ programs include its lead product candidate, vebreltinib, a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort global clinical trial, and uproleselan, a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in a Phase 3 clinical trial in China. For more information, please visit .

Investor Contact:

Eric Ribner

LifeSci Advisors, LLC

(646) 751-4363

 



EN
04/09/2024

Underlying

APLMAPOLLOMICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APOLLOMICS INC.

 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Reports First Half 2025 Financial Results

Apollomics Reports First Half 2025 Financial Results FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2.1 million, compared to $9.8 million as of December 31, 202...

December 22, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Settlement of Cayman Litigation FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims b...

November 19, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Changes to its Board of Directors and Composition...

Apollomics Announces Changes to its Board of Directors and Composition of Committees FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16...

November 18, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Continued Listing on The Nasdaq Stock Market Foll...

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation Nasdaq Hearing Cancellation and Continued Listing FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (...

October 15, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics, Inc. Company Operational Continuity Update

Apollomics, Inc. Company Operational Continuity Update FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer,...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch